IL232385A - Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder - Google Patents

Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder

Info

Publication number
IL232385A
IL232385A IL232385A IL23238514A IL232385A IL 232385 A IL232385 A IL 232385A IL 232385 A IL232385 A IL 232385A IL 23238514 A IL23238514 A IL 23238514A IL 232385 A IL232385 A IL 232385A
Authority
IL
Israel
Prior art keywords
hyperuricemia
halofenate
gout
medicaments
patients
Prior art date
Application number
IL232385A
Other languages
English (en)
Hebrew (he)
Other versions
IL232385A0 (en
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of IL232385A0 publication Critical patent/IL232385A0/en
Publication of IL232385A publication Critical patent/IL232385A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL232385A 2011-11-04 2014-04-30 Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder IL232385A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (2)

Publication Number Publication Date
IL232385A0 IL232385A0 (en) 2014-06-30
IL232385A true IL232385A (en) 2017-10-31

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232385A IL232385A (en) 2011-11-04 2014-04-30 Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder

Country Status (14)

Country Link
EP (1) EP2775835A4 (enrdf_load_stackoverflow)
JP (1) JP6047172B2 (enrdf_load_stackoverflow)
KR (1) KR101848122B1 (enrdf_load_stackoverflow)
CN (1) CN104066323A (enrdf_load_stackoverflow)
AU (1) AU2011380509B2 (enrdf_load_stackoverflow)
BR (1) BR112014010693A2 (enrdf_load_stackoverflow)
CA (1) CA2859689C (enrdf_load_stackoverflow)
CL (1) CL2014001156A1 (enrdf_load_stackoverflow)
IL (1) IL232385A (enrdf_load_stackoverflow)
MX (1) MX354846B (enrdf_load_stackoverflow)
NZ (1) NZ624714A (enrdf_load_stackoverflow)
SG (1) SG11201402027PA (enrdf_load_stackoverflow)
WO (1) WO2013066352A1 (enrdf_load_stackoverflow)
ZA (1) ZA201403574B (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
CN105851522A (zh) * 2014-07-25 2016-08-17 许伟琦 一种防止尿路结石的饲料
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CN102643241B (zh) * 2007-11-27 2015-01-21 亚德生化公司 化合物和组合物以及使用方法

Also Published As

Publication number Publication date
CL2014001156A1 (es) 2015-01-16
KR20140123927A (ko) 2014-10-23
KR101848122B1 (ko) 2018-04-11
IL232385A0 (en) 2014-06-30
MX2014005399A (es) 2015-04-08
CA2859689A1 (en) 2013-05-10
NZ624714A (en) 2016-01-29
WO2013066352A1 (en) 2013-05-10
EP2775835A4 (en) 2015-07-29
JP2014532759A (ja) 2014-12-08
MX354846B (es) 2018-03-22
BR112014010693A2 (pt) 2020-11-10
SG11201402027PA (en) 2014-09-26
EP2775835A1 (en) 2014-09-17
CN104066323A (zh) 2014-09-24
CA2859689C (en) 2018-05-22
JP6047172B2 (ja) 2016-12-21
AU2011380509B2 (en) 2016-05-19
ZA201403574B (en) 2015-11-25
AU2011380509A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
ZA201403795B (en) Formulations for the treatment of diabetes
IL232384A (en) Use of lupanate compounds or lupanic acid for the preparation of anti-gout drugs
SG11201401907TA (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
PL2613798T3 (pl) Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
IL223289A0 (en) Treatment of type 2 diabetes
HUS2000020I1 (hu) Ciklezonid a légúti betegségek kezelésére lovaknál
IL233351A (en) Use of apolipoprotein a – iv without glycosylation for the preparation of diabetes medications
ZA201403575B (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
IL232385A (en) Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder
PL2560662T3 (pl) Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy
IL228891A (en) 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease
IL221747A (en) Inhibits Sodium / Phosphate Co-Transmission through the Aryl Fluorophosphate Peripheral Membrane
DK2656075T3 (da) Fremgangsmåde til optimering af behandlingen af patienter med biologiske lægemidler
HK1193342A (en) Pharmaceutical combination for use in the treatment of diabetes type 2
IL232294A0 (en) Preparations for the treatment of diabetes
SG10201609202PA (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
ZA201307614B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
HK1192448A (en) Compounds for use in the treatment of feline retroviral infections
GB201009893D0 (en) Electrochemical reactor for the treatment of fluids
PL391810A1 (pl) Nowe sole ziprasidonu oraz sposoby ich otrzymywania
HK1181301A (en) Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed